Growth Capitalist (https://growthcapitalist.com/tag/biomed/page/27/)
Sionix Corp. (SINX) announced that it has raised $1 million in a Convertible Senior Notes transaction. The fixed conversion price was not disclosed and the Investors recieved an undisclosed amount of warrants. Trump Securities acted as the exclusive agent on the transaction, and the investors were not disclosed. See the PlacementTracker Deal Summary.
Insmed (INSM) announced that it has raised $25.7 million in a Registered Direct transaction with investors Ayer Capital, Quaker Partners and RA Capital. The common stock was sold at $4.07 per share, a 0% discount to the market price of INSM at deal announcement. Additionally, the Company announced that it will raise an additional $2 million on Oct. 31, 2012 at a price per share that has yet to be disclosed. See the PlacementTracker Deal Summary.
TherapeuticsMD (TXMD) announced that it has raised $8.5 million in a Common Stock transaction. The common stock was sold at $2.15 per share, an approximate 38% discount to the market price ($3.46) of TXMD at deal announcement. Warrants, the Placement Agent, and the investors were not disclosed. See the PlacementTracker Deal Summary.
NuPathe Inc. (PATH) announced that it has raised $28 million in a Convertible Preferred Stock transaction. The company focuses on treatments for psychiatric and neuropathic disorders. The fixed conversion price of the Convertible Preferred Stock is $2.00 per share, an approximate 53.92% discount to the market price ($4.34) of PATH at deal announcement. A series of 14 million 60-Month Warrants with an exercise price of $2.00 per share (53.92% discount) was issued to the investors in this transaction. See the PlacementTracker Deal Summary.
